Romania Oncology Clinical Trials Market Report 2022 to 2030

Romania Oncology Clinical Trials Market Analysis

$ 3999

Romania's oncology clinical trials market is projected to grow from $36.7 Mn in 2022 to $57.4 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. The market will be driven by the country’s rising incidence of cancers and supportive regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Pfizer Inc. & Biofarm SA.

ID: IN10ROCT006 CATEGORY: Clinical Trials GEOGRAPHY: Romania AUTHOR: Vidhi Upadhyay

Buy Now

Romania Oncology Clinical Trials Market Executive Summary

Romania's oncology clinical trials market is projected to grow from $36.7 Mn in 2022 to $57.4 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. Romania is the twelfth-largest nation in Europe and the seventh-most populated member state of the European Union, with a rising population of 19.4 million people. With clinical research activities on the surge, it already hosts more than 500 clinical studies. According to Globocan 2020, the number of new cases of cancer was 98,886 while the fatalities recorded were 54,486. Colorectum cancer (13.1%), Lung cancer (12.3%) & Breast cancer (12.2%) accounted for most incidences in the country.

With a big patient population, qualified clinical researchers, and a supportive government, the nation provides an ideal setting for conducting oncology clinical trials. Clinical trials in Romania often concentrate on cancers with a high incidence, such as lung cancer, breast cancer, and colorectal cancer. These studies attempt to improve the diagnosis and treatment of certain disorders, as well as to lessen their effect on the patient population. In oncology clinical trials, Romania is using cutting-edge technology and approaches such as precision medicine, biomarker testing, and real-world evidence. These technologies are assisting in improving the accuracy and efficiency of clinical studies, resulting in improved patient results. Oncology clinical trials are increasing in Romania, with a focus on cancer types with a high prevalence and the use of novel technology. Partnerships with foreign sponsors, the increasing importance of patient advocacy organizations, and a better regulatory environment are all contributing to the expansion of oncology clinical trials in Romania.

romania oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Romanians, Hungarians, Bulgarians, Germans, Ruthenians and Ukrainians, Serbs, Croats, Jews, Greeks, Armenians, Turks, and Romani people comprise the country's varied population. Romania's population is relatively youthful, with a median age of 40 years. Romania has a big patient population, which makes recruiting subjects for clinical trials simpler. It has cheaper labour and operational expenses than other European nations, which translates into reduced clinical trial expenditures. Romania has a highly competent medical workforce, with many physicians and nurses. The Romanian regulatory framework is competent and favourable to clinical trials, with shortened approvals and study completion procedures. Romania has a well-developed healthcare system, with modern medical facilities and easy access to medical supplies and equipment.

Market Restraints

There are however some growth constraints that must be addressed in order for this potential to be achieved. One of the biggest constraints is a lack of financing, which might make it difficult for local researchers to launch and perform clinical studies on their own. Moreover, regulatory hurdles, limited access to specialised facilities and equipment, patient recruitment and retention, and a lack of cooperation among stakeholders may all contribute to clinical trial inefficiency.

Competitive Landscape

Key Players

Roche Holding AG
Pfizer Inc.
Novartis International AG
Merck & Co., Inc.
AstraZeneca plc
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
Biofarm SA (ROU)
Gedeon Richter Romania SRL (ROU)

Notable Insights

December 2022, Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand treatment, was authorised by the European Commission (EC) today. Pluvicto® is licenced for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC)
August 2022, Can-Fite BioPharma Ltd., a biotechnology company developing a pipeline of proprietary small molecule drugs to treat inflammatory, cancer, and liver diseases, announced that its liver drug candidate Namodenoson has received compassionate use approval in Romania for the treatment of patients with advanced liver cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.